Long-term reductions in disease impact in patients with chronic migraine following preventive treatment with eptinezumab

Long-term reductions in disease impact in patients with chronic migraine following preventive treatment with eptinezumab

Abstract Background Eptinezumab is an anti-calcitonin gene-related peptide humanized monoclonal antibody approved for the preventive treatment of migraine in adults. The PREVAIL study demonstrated a favorable safety profile with sustained reductions in overall migraine-related burden in patients wit...

Full description

Bibliographic Details
Main Authors: Andrew Blumenfeld, Anders Ettrup, Joe Hirman, Bjarke Ebert, Roger Cady
Format: Article
Language:English
Published: BMC 2022-07-01
Series:BMC Neurology
Subjects:
Eptinezumab
Chronic migraine
Patient-reported outcomes
CGRP monoclonal antibody
Online Access:https://doi.org/10.1186/s12883-022-02774-3

Internet

https://doi.org/10.1186/s12883-022-02774-3

Similar Items